AstraZeneca (CHIX:AZNL) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:AZNL AstraZeneca PLC CHIX:AZNL
91 GF Score
Price £120.20
GF Value £134.38
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca SpecialCharges?

Special Charges only applies to banks.

CHIX:AZNL
91GF Score
AstraZeneca PLC CHIX:AZNL
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AstraZeneca (CHIX:AZNL) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of £120.20 is trading 10.6% below its estimated GF Value™ of £134.38. GuruFocus considers AstraZeneca to be Modestly Undervalued.

Key valuation signals for CHIX:AZNL:

  • SpecialCharges:
  • GF Value™: £134.38 vs. price of £120.20 (10.6% below fair value)
  • GF Score™: 91/100 with 1 warning sign

No single metric tells the full story. See the CHIX:AZNL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
91GF Score

Get the complete analysis for CHIX:AZNL

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£120.20
Price
£134.38
GF Value